insights_auto
Pse është rritur CRSP 3,11%?
Zhytu më thellëchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
50,07 US$
arrow_upward
+3,11%(+1,51) 1D
49,35 US$
arrow_downward
-1,44% (-0,72)bedtimeJashtë orarit
Mbyllur: 6 nën, 4:00:01 m.d., GMT-5 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për CRSP...
Hap
48,98 US$
I lartë
50,27 US$
I ulët
48,41 US$
Kapitalizimi i tregut
4,86 mld
Vëllimi mesatar
1,46 mln
Vëllimi
1,24 mln
Maksimumi 52-javor
63,45 US$
Minimumi 52-javor
44,12 US$
Fitimet për aksion
-4,75 US$
Beta
1,49
Aksionet në qarkullim
97,00 mln
Numri i punonjësve
393
Hap
48,98 US$
I lartë
50,27 US$
I ulët
48,41 US$
Kapitalizimi i tregut
4,86 mld
Vëllimi mesatar
1,46 mln
Vëllimi
1,24 mln
Maksimumi 52-javor
63,45 US$
Minimumi 52-javor
44,12 US$
Fitimet për aksion
-4,75 US$
Beta
1,49
Aksionet në qarkullim
97,00 mln
Numri i punonjësve
393
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Investing.com Canada
·
3 orë më parë
Form 144 CRISPR THERAPEUTICS AG For: 6 November By Investing.com
Zacks
·
15 orë më parë
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Yahoo Finance UK
·
16 orë më parë
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Yahoo Finance
·
2 ditë më parë
CRISPR Therapeutics AG (CRSP) Stock Forecasts
Profili
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
Rreth Crispr Therapeutics AG
Drejtori ekzekutivSamarth Kulkarni
Punonjësit393
Themeluar më2013
SeliaZug, Kantoni Zug, Zvicër
SektoriHealth Care
Industria-
Uebsajticrisprtx.com